466 related articles for article (PubMed ID: 30158205)
1. IQOS: examination of Philip Morris International's claim of reduced exposure.
St Helen G; Jacob Iii P; Nardone N; Benowitz NL
Tob Control; 2018 Nov; 27(Suppl 1):s30-s36. PubMed ID: 30158205
[TBL] [Abstract][Full Text] [Related]
2. PMI's own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes.
Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s9-s12. PubMed ID: 30131374
[TBL] [Abstract][Full Text] [Related]
3. Revolution or redux? Assessing IQOS through a precursor product.
Elias J; Dutra LM; St Helen G; Ling PM
Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
[TBL] [Abstract][Full Text] [Related]
4. Assessment of industry data on pulmonary and immunosuppressive effects of IQOS.
Moazed F; Chun L; Matthay MA; Calfee CS; Gotts J
Tob Control; 2018 Nov; 27(Suppl 1):s20-s25. PubMed ID: 30158203
[TBL] [Abstract][Full Text] [Related]
5. Heated tobacco products likely appeal to adolescents and young adults.
McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
[TBL] [Abstract][Full Text] [Related]
6. Free-Base and Total Nicotine, Reactive Oxygen Species, and Carbonyl Emissions From IQOS, a Heated Tobacco Product.
Salman R; Talih S; El-Hage R; Haddad C; Karaoghlanian N; El-Hellani A; Saliba NA; Shihadeh A
Nicotine Tob Res; 2019 Aug; 21(9):1285-1288. PubMed ID: 30476301
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial function is impaired by aerosol from a single IQOS HeatStick to the same extent as by cigarette smoke.
Nabavizadeh P; Liu J; Havel CM; Ibrahim S; Derakhshandeh R; Jacob Iii P; Springer ML
Tob Control; 2018 Nov; 27(Suppl 1):s13-s19. PubMed ID: 30206183
[TBL] [Abstract][Full Text] [Related]
8. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
McKelvey K; Baiocchi M; Halpern-Felsher B
Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
[TBL] [Abstract][Full Text] [Related]
9. Light and mild redux: heated tobacco products' reduced exposure claims are likely to be misunderstood as reduced risk claims.
Popova L; Lempert LK; Glantz SA
Tob Control; 2018 Nov; 27(Suppl 1):s87-s95. PubMed ID: 30209208
[TBL] [Abstract][Full Text] [Related]
10. IQOS labelling will mislead consumers.
McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
[TBL] [Abstract][Full Text] [Related]
11. Analysis of mainstream emissions, secondhand emissions and the environmental impact of IQOS waste: a systematic review on IQOS that accounts for data source.
El-Kaassamani M; Yen M; Talih S; El-Hellani A
Tob Control; 2022 May; ():. PubMed ID: 35568394
[TBL] [Abstract][Full Text] [Related]
12. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
Lempert LK; Bialous S; Glantz S
Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Tobacco Heating System 2.2. Part 3: Influence of the tobacco blend on the formation of harmful and potentially harmful constituents of the Tobacco Heating System 2.2 aerosol.
Schaller JP; Pijnenburg JPM; Ajithkumar A; Tricker AR
Regul Toxicol Pharmacol; 2016 Nov; 81 Suppl 2():S48-S58. PubMed ID: 27793747
[TBL] [Abstract][Full Text] [Related]
14. Modelling the impact of a new tobacco product: review of Philip Morris International's Population Health Impact Model as applied to the IQOS heated tobacco product.
Max WB; Sung HY; Lightwood J; Wang Y; Yao T
Tob Control; 2018 Nov; 27(Suppl 1):s82-s86. PubMed ID: 30275170
[TBL] [Abstract][Full Text] [Related]
15. PMI's IQOS and cigarette ads in Israeli media: a content analysis across regulatory periods and target population subgroups.
Khayat A; Berg CJ; Levine H; Rodnay M; Abroms L; Romm KF; Duan Z; Bar-Zeev Y
Tob Control; 2024 Mar; 33(e1):e54-e61. PubMed ID: 36418166
[TBL] [Abstract][Full Text] [Related]
16. Should IQOS Emissions Be Considered as Smoke and Harmful to Health? A Review of the Chemical Evidence.
Uguna CN; Snape CE
ACS Omega; 2022 Jul; 7(26):22111-22124. PubMed ID: 35811880
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 3R4F cigarette smoke and IQOS heated tobacco product aerosol emissions.
Kärkelä T; Tapper U; Kajolinna T
Environ Sci Pollut Res Int; 2022 Apr; 29(18):27051-27069. PubMed ID: 34935111
[TBL] [Abstract][Full Text] [Related]
18. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
Robichaud MO; Puryear T; Cohen JE; Kennedy RD
Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
[TBL] [Abstract][Full Text] [Related]
19. IQOS marketing strategies at point-of-sales: a cross-sectional survey with retailers.
Bar-Zeev Y; Berg CJ; Khayat A; Romm KF; Wysota CN; Abroms LC; Elbaz D; Levine H
Tob Control; 2023 Aug; 32(e2):e198-e204. PubMed ID: 35140170
[TBL] [Abstract][Full Text] [Related]
20. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
